Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niall M Byrne

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Personalized Medicine|January 20, 2021
Radiation Response in the Tumour Microenvironment: Predictive Biomarkers and Future PerspectivesNiall M Byrne, Prajakta Tambe, Jonathan A Coulter
JBMR Plus|March 29, 2019
Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic OpportunitiesNiall M Byrne, Matthew A Summers, Michelle M McDonald
Cancers|December 15, 2019
Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic DevelopmentJie Feng, Niall M Byrne, Wafa Al Jamal, et al.
Chemical Communications (Cambridge, England)|July 14, 2012
Microbubble-sonosensitiser conjugates as therapeutics in sonodynamic therapyNikolitsa Nomikou, Colin Fowley, Niall M Byrne, et al.
Drug Delivery and Translational Research|July 15, 2023
Urethane dimethacrylate-based photopolymerizable resins for stereolithography 3D printing: A physicochemical characterisation and biocompatibility evaluationGiulia Pitzanti, Valentyn Mohylyuk, Francesca Corduas, et al.
Journal of Cellular Physiology|July 21, 2015
Nitric Oxide Up-Regulates RUNX2 in LNCaP Prostate Tumours: Implications for Tumour Growth In Vitro and In VivoHeather Nesbitt, Gillian Browne, Katie M O'Donovan, et al.
Cell Communication and Signaling : CCS|April 2, 2025
Atovaquone-induced activation of the PERK/eIF2α signaling axis mitigates metabolic radiosensitisationJie Feng, Varun Pathak, Niall M Byrne, et al.
International Journal of Cancer|August 24, 2012
Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment responseLouise Ming, Niall M Byrne, Sarah Nicole Camac, et al.
ACS Biomaterials Science & Engineering|January 28, 2026
Metabolic Radiosensitization by Targeting Lactate Metabolism with Microfluidic Liposomal NanocarriersMeabh Doherty, Jie Feng, Tongchuan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2016
Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant ProgressionHeather Nesbitt, Niall M Byrne, S Nicole Williams, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Personalized Medicine|January 20, 2021
Radiation Response in the Tumour Microenvironment: Predictive Biomarkers and Future PerspectivesNiall M Byrne, Prajakta Tambe, Jonathan A Coulter
JBMR Plus|March 29, 2019
Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic OpportunitiesNiall M Byrne, Matthew A Summers, Michelle M McDonald
Cancers|December 15, 2019
Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic DevelopmentJie Feng, Niall M Byrne, Wafa Al Jamal, et al.
Chemical Communications (Cambridge, England)|July 14, 2012
Microbubble-sonosensitiser conjugates as therapeutics in sonodynamic therapyNikolitsa Nomikou, Colin Fowley, Niall M Byrne, et al.
Drug Delivery and Translational Research|July 15, 2023
Urethane dimethacrylate-based photopolymerizable resins for stereolithography 3D printing: A physicochemical characterisation and biocompatibility evaluationGiulia Pitzanti, Valentyn Mohylyuk, Francesca Corduas, et al.
Journal of Cellular Physiology|July 21, 2015
Nitric Oxide Up-Regulates RUNX2 in LNCaP Prostate Tumours: Implications for Tumour Growth In Vitro and In VivoHeather Nesbitt, Gillian Browne, Katie M O'Donovan, et al.
Cell Communication and Signaling : CCS|April 2, 2025
Atovaquone-induced activation of the PERK/eIF2α signaling axis mitigates metabolic radiosensitisationJie Feng, Varun Pathak, Niall M Byrne, et al.
International Journal of Cancer|August 24, 2012
Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment responseLouise Ming, Niall M Byrne, Sarah Nicole Camac, et al.
ACS Biomaterials Science & Engineering|January 28, 2026
Metabolic Radiosensitization by Targeting Lactate Metabolism with Microfluidic Liposomal NanocarriersMeabh Doherty, Jie Feng, Tongchuan Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2016
Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant ProgressionHeather Nesbitt, Niall M Byrne, S Nicole Williams, et al.
Pageof 2